{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.74","value":"3.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The mean Investigator's rating of the change in subject's signs and symptoms of Cushing's syndrome from Baseline (Entry into C1073-415) to Endpoint on the Physician's Global Assessment of Disease Severity was ranked on a 9-point scale (9 = much worse, 7 = worse, 5 = no change, 3 = better, 1 = much better). Higher scores indicate more severe illness. Scoring was done at all visits except the 6 Week Follow-up visit; the final visit result (Endpoint) is reported here.\n\nThe instruction was \"Rate the change in the subject's signs and symptoms of Cushing's from Baseline (1 = much better to 9 = much worse)\".","dispersionType":"Standard Deviation","groups":[{"description":"mifepristone at doses from 300 mg/day up to 1200 mg/day daily","id":"OG000","title":"Open-label"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Up to three years.","title":"The Long-term Benefit of Mifepristone Treatment in Cushing's Syndrome as Measured by Changes in the Score on the Physician's Global Assessment of Disease Severity","type":"SECONDARY","unitOfMeasure":"units on a scale"}